| 論文種別 | 症例報告 |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Severe Anti-CV2/CRMP5, Anti-Hu, and Anti-SOX1 Antibody-Positive Paraneoplastic Neurological Syndrome Associated With Tumor Recurrence During Atezolizumab Therapy. |
| 掲載誌名 | 正式名：Cureus 略 称：Cureus ISSNコード：21688184/21688184 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 17(12),pp.e99224 |
| 著者・共著者 | Rie Tohge, Kazuki Utsumi, Katsuaki Miki, Chenyao Wang, Mitsuaki Oki, Chihiro Fujii, Takayuki Kondo |
| 発行年月 | 2025/12 |
| 概要 | We report a case of an 80-year-old man with small-cell lung cancer who developed paraneoplastic neurological syndrome (PNS) after four years of immune checkpoint inhibitor (ICI) therapy (atezolizumab). The patient presented with bilateral optic neuropathy, parkinsonism, and truncal ataxia. MRI revealed lesions in the basal ganglia and medial temporal lobes. Serological testing revealed a marked elevation of tumor markers, along with the presence of anti-CV2/CRMP5, anti-Hu, and anti-SOX1 antibodies. PNS onset may be primarily triggered by tumor recurrence, with long-term ICI exposure further amplifying the underlying immune response. |
| DOI | 10.7759/cureus.99224 |
| PMID | 41542009 |